Kaspofungin Rhei

Caspofungin, the active ingredient in Kaspofungin Rhei, is an echinocandin presented as an intravenous solution for intravenous use. It treats serious invasive fungal infections such as invasive candidiasis, esophageal candidiasis, and invasive aspergillosis in adult patients requiring hospital‑based therapy.

GNH USA supplies Kaspofungin Rhei as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide, with distribution aligned to EU market standards. The product meets European quality specifications and is available for bulk procurement.

Caspofungin is an echinocandin antifungal used to manage serious invasive fungal infections. - Invasive candidiasis: clears bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: eradicates Candida infection of the esophagus. - Invasive aspergillosis: treats Aspergillus infections in patients unable to use alternative agents.

Caspofungin may cause a range of adverse reactions, from mild infusion‑related events to rare but severe systemic effects.

Common Side Effects: - Fever: transient temperature rise during infusion. - Nausea: mild gastrointestinal upset. - Headache: occasional mild to moderate pain. - Rash: skin erythema or pruritus. - Elevated liver enzymes: mild transaminase increase. - Infusion‑related reactions: flushing, chills, or rigors.

Serious or Rare Side Effects: - Severe hypersensitivity: anaphylaxis or angioedema. - Hepatic failure: marked elevation of bilirubin or transaminases. - Renal toxicity: acute kidney injury. - Severe hypotension: sudden drop in blood pressure during infusion. - Stevens‑Johnson syndrome: extensive skin detachment. - Fatal outcomes: rare cases of treatment‑related mortality.

Caspofungin requires careful monitoring and specific handling precautions. - Liver function monitoring: assess transaminases and bilirubin before and during therapy. - Renal function assessment: evaluate serum creatinine and adjust if needed. - Hypersensitivity evaluation: discontinue if severe allergic reaction occurs. - Cardiac caution: monitor blood pressure during infusion, especially in patients with pre‑existing heart disease. - Hepatic impairment adjustment: consider dose modification in severe liver disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Caspofungin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Rifampin or other strong CYP inducers: may markedly reduce caspofungin exposure. - Concurrent azole antifungals (e.g., fluconazole, voriconazole): can increase caspofungin plasma levels.

Moderate Interactions (Monitor Closely): - Nephrotoxic agents (e.g., aminoglycosides): monitor renal function. - Hepatotoxic drugs (e.g., acetaminophen overdose): watch liver enzymes. - Immunosuppressants (e.g., cyclosporine): observe for additive toxicity. - Other antifungal agents: assess for overlapping toxicity. - Concomitant anticoagulants: monitor coagulation parameters.